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Purpose: The aim of this study is to assess the role of contrast-enhanced ultrasonography (CEUS) 
in the detection of liver metastases in cancer patients with geographic liver fatty deposition on 
greyscale ultrasonography (US).
Methods: Thirty-seven consecutive cancer patients (24 women and 13 men; age, 33 to 80 years; 
mean, 58.1 years) with geographic liver fatty deposition, but without any detectable focal liver 
lesion on greyscale US, underwent sulphur hexafluoride-enhanced US. Two readers reported 
by consensus the presence, size, and location of any detected lesion. All patients underwent 
magnetic resonance imaging (MRI) as a confirmatory study. Sensitivity, specificity, positive and 
negative predictive values (PPV and NPV), and accuracy were calculated.
Results: Seven focal liver lesions (size, 4 to 10 mm; mean, 6.1 mm) were detected in 4/37 
patients (10.8%): four metastases (size, 5 to 10 mm; mean, 6.7 mm) were detected both by 
CEUS and MRI, with one hemangioma and two cysts (size range, 4 to 6 mm; mean, 5.3 mm) 
detected by MRI only. In 1/37 patients (2.7%), CEUS misdiagnosed geographic fatty change as 
three metastases. In 32/37 patients (86.5%), no lesions were detected. Sensitivity, specificity, 
PPV, NPV, and accuracy of CEUS were 100% (95% confidence Interval [CI], 1.000 to 1.000), 
97.1% (95% CI, 0.914 to 1.027), 75%, 100%, and 97.3%, respectively. No statistically 
significant differences were found between CEUS and MRI in the detection of focal liver lesions 
(P=0.480), whereas both of them performed better than baseline US (P<0.001). 
Conclusion: CEUS improves the detection of liver metastases in cancer patients with geographic 
liver fatty deposition on greyscale US.
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Introduction
The liver is a very common site for the spread of malignancy, and follow-up programs for patients 
with cancer, including liver imaging performed by means of transabdominal ultrasonography (US), are 
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reported to improve survival [1]. 
Nevertheless, in clinical practice US may show equivocal results, 
with a sensitivity ranging from 40% to 80% according to the 
diameter of lesions and the experience of the sonologist [2,3]. Fatty 
infiltration of the liver, often induced by chemotherapy, may further 
worsen US performance in this crucial task [4]. In particular, unusual 
and heterogeneous forms of fatty deposition, such as geographic 
liver fatty deposition, may prevent greyscale US from reliably ruling 
out the presence of liver metastases in cancer patients, even in the 
absence of any overt and/or suspect focal liver lesion [5]. More 
recently, the introduction of contrast-enhanced ultrasonography 
(CEUS) has led to a dramatic improvement in diagnostic accuracy 
of US in the detection of liver metastases, when compared to 
conventional greyscale US [2,6]. CEUS has also been reported to 
improve the characterization of focal hepatic lesions in patients with 
fatty liver and in diagnosing both focal fatty infiltration and sparing 
[7-9]. Hence, we hypothesized that CEUS might be an effective 
tool in the detection of liver metastases during follow-up of cancer 
patients with geographic liver fatty deposition, but without any 




This prospective study was approved by the Ethics Review Board 
of our institution. All patients gave their full informed consent 
before the CEUS examination. The implemented procedure was in 
accordance with the Declaration of Helsinki [10].
Between June 2013 and December 2013, 37 consecutive patients 
(24 women and 13 men; age range, 33 to 80 years; mean, 58.1 
years) were enrolled in this study. Enrolled patients were referred to 
our institution for an abdominal US for detection of liver metastases 
during postsurgical follow-up (interval range, 8 to 222 months; 
mean, 56.2 months) of pathologically proven primary malignancies. 
Liver CEUS examinations were performed immediately following 
the standard US examination that diagnosed the geographic 
fatty infiltration, on the basis of the following inclusion criteria: 
(1) the absence of any overt and/or suspect focal liver lesion on 
preoperative US, including lesions showing US features of simple 
cyst, typical hemangioma and/or typical focal fatty sparing; (2) 
the presence of geographic liver fatty deposition on greyscale US, 
defined as patchy areas of increased liver reflectivity without a 
mass effect and/or vessel displacement [5]. The following exclusion 
criteria were also considered: (1) incomplete visibility of the liver 
parenchyma on preoperative US due to intervening bowel gas or 
patient body habitus; (2) clinical history of previously detected liver 
metastases with US, computed tomography (CT), and/or magnetic 
resonance imaging (MRI); (3) clinical history of liver metastases 
previously treated by radiofrequency or surgical procedures; (4) 
presence of local or distant nodal metastatic spread; (5) positive 
tumoral serum markers; (6) presence of critical illness and/or severe 
heart disease; (7) presence of allergy to sulphur hexafluoride 
(SonoVue); and (8) lack of final diagnosis proved by means of an 
adequate standard of reference (SOR). No patients were excluded 
due to severe steatosis.
All studied patients had previously received chemotherapy 
or chemo-radiotherapy for primary cancer located outside the 
liver: breast ductal or lobular carcinoma (n=18), colorectal 
adenocarcinoma (n=14), gastrointestinal stromal tumour (n=1), 
intestinal neuroendocrine tumour (n=1), pleural mesothelioma (n=1), 
endometrial adenocarcinoma (n=1), and ovarian adenocarcinoma 
(n=1). Also, all patients had undergone a previous imaging 
follow-up at our institution, which confirmed the absence of liver 
metastases and geographic liver fatty deposition.
US Technique
Two experienced radiologists (more than 15 years experience in 
CEUS of the liver), who were aware of the patients’ clinical histories, 
performed US scanning by means of either a MyLab Twice (Esaote 
Biomedica, Genoa, Italy) or an iU22 unit (Philips Ultrasound, Bothell, 
WA, USA), both provided with a multifrequency convex array probe 
(CA541 1-8 MHz and C 5-2 MHz) and contrast-specific imaging 
software (Contrast-Tuned and Pulse Inversion, respectively). A 
baseline survey examination, including a colour/power and pulsed 
Doppler analysis, was performed. Once set, the US parameters, 
such as focal zone and time gain compensation, were not changed 
during the course of the study. The US contrast agent used in the 
present study was SonoVue (Bracco, Milan, Italy), which was injected 
intravenously as a 2.4 mL bolus (equivalent to a 0.003 mL/kg for 
70 kg body weight) followed by 10 mL of normal sterile saline flush 
by using a 20- or 22-gauge peripheral intravenous cannula. A low 
frame-rate (5 Hz) and a very low mechanical index, ranging from 0.05 
to 0.08, were used for real-time imaging. One focus was positioned 
below the level of the lesion. Two consecutive examinations in the 
same session were performed with an interval time of at least 15 
minutes to allow for contrast clearance of the previous contrast 
medium injection. The first examination, encompassing the right 
lobe of the liver, was performed with a subcostal approach and the 
patient lying on the left flank, whereas the second examination, 
encompassing the left lobe, was performed with an anterior 
abdominal approach and the patient lying supine. Each examination 
lasted about 5 minutes after bolus injection. Digital cineloops were 
registered both at baseline and during the whole post-contrast US 
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scanning up to 5 minutes after the beginning of contrast agent 
bolus injection. All cineloops were digitally stored as raw-data on 
a PC-based workstation connected to the US units via a standard 
Ethernet link.
On-Site Image Analysis
Immediately after the completion of each CEUS procedure, the 
two examiners subjectively reviewed all cineloops offline but on 
screen, and evaluated by consensus the dynamic enhancement 
pattern of liver parenchyma and reported the presence, size, and 
location (according to the Couinaud classification system) of any 
detected lesion. For the purposes of this study, which is focused 
on cancer patients, any hypoechoic solid lesion (darker than the 
surrounding liver) in the late phase was considered malignant, since 
all metastases show this feature at CEUS, without any reported 
exception [11].  
Off-Site Image Analysis
Two independent and experienced radiologists (with more than 10 
years experience in the use and interpretation of CEUS) randomly 
reviewed all cineloops offline but on screen. Neither reader was 
involved in the scanning, and they were blinded to the final 
diagnosis, as well as to the identification, clinical histories, and other 
imaging findings of the patients.
The examinations were randomly and independently assessed in 
separate sessions. The readers were asked to evaluate the US in the 
same fashion as previously described for on-site image analysis.
Standards of Reference
All patients underwent MRI performed with a 1.5 T MR unit (Signa 
Excite, General Electric, Healthcare, Milwaukee, WI, USA) using a 
phased-array multicoil as a receiver coil. The MRI protocol included 
axial pre-contrast images acquired with T2-weighted fast-spin 
echo sequence (TR/TE, 4,000/76 msec; section thickness, 5-6 
mm) and T1-weighted axial in-phase and out-of-phase gradient-
recalled-echo (GRE) sequence (TR/TE, 140/2.2-4.4 msec; section 
thickness, 5-6 mm). Dynamic studies were performed with three-
dimensional, fat-suppressed, T1-weighted GRE sequence (LAVA-TR/
TE, 3.8/1.2 msec; FA 12; slice thickness, 4.4 mm; intersection gap, 2 
mm; FOV, 44 cm; matrix, 256×256) using a bolus-tracking system. 
Images were acquired on the axial plane immediately before and 
after intravenous injection of either 0.1 mmol/kg body weight of 
gadobenate dimeglumine (MultiHance, Bracco, Italy) at 2 mL/sec or 
0.025 mmol/kg body weight of gadoxetic acid at 1 mL/sec through 
a 20-gage intravenous catheter by means of a power injector 
(Medrad Spectris Solaris EP MR Injection System, Bayer HealthCare, 
Wuppertal, Germany), followed by a 20-mL saline flush at the same 
injection rate. Scanning delays after automatic detection of contrast 
bolus were 18, 60, 180, and 300 seconds, respectively, for the 
acquisition of the arterial, portal-venous, 3-minute, and 5-minute 
phase. Hepatobiliary phases were obtained 120 minutes after the 
injection of contrast material, with the same scanning parameters. 
The interval between the MRI and the CEUS was 1-10 days (mean 
interval, 7 days).
Two experienced radiologists (with more than 15 years experience 
in MRI of the liver), not involved in the US scanning and not aware 
of clinical history, evaluated magnetic resonance (MR) examinations 
by consensus. Diagnostic criteria for liver metastases and fatty 
change of the liver at CEUS and MRI with hepatocellular specific 
contrast agent are reported in Tables 1 and 2, respectively [8,12-14].
Statistical Analysis
First, detection of liver metastases was analysed with patient-
by-patient analysis. The Wilcoxon signed rank test was employed 
to compare paired data from baseline US, CEUS, and contrast-
enhanced MR. 
Second, detailed lesion-by-lesion analysis was performed and 
sensitivity, specificity (diagnostic performance) for baseline US, 
CEUS, and contrast-enhanced CT were compared by the two-tailed 
McNemar test with a continuity correction. A P-value <0.05 was 
Table 1. Diagnostic criteria for liver metastases 
Contrast-enhanced ultrasonography 
- Hypovascular appearance in the extended portal-venous phase 
regardless of contrast-enhancement behaviour in the arterial phase
Gd-BOPTA-enhanced magnetic resonance imaging 
- Intermediately intense signal on T2-weighted images
- Hypointense signal on T1-weighted images
- Hypervascular appearance with diffuse enhancement or hypovascular 
appearance±peripheral rim-like enhancement at arterial-dominant 
phase
- Hypovascular appearance at portal-venous and 2 hr after Gd-BOPTA 
injection
Gd-BOPTA, gadobenate dimeglumine.
Table 2. Diagnostic criteria for fatty change of the liver
Contrast-enhanced ultrasonography 
- Area homogeneously iso-enhancing to liver parenchyma in all 
vascular phases
Gd-BOPTA-enhanced magnetic resonance imaging 
- Area of increased signal on T1-weighted sequences; in-phase/out-of-
phase: signal drop-out in out-of-phase imaging
Gd-BOPTA, gadobenate dimeglumine.
CEUS in cancer patients and diffuse liver steatosis
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considered to indicate a statistically significant difference in all tests.
Cohen's kappa was calculated to assess inter-operator agreement. 
Agreement was graded as poor (≤0.20), moderate (0.20 to 0.40), 
fair (0.40 to 0.60), good (0.60 to 0.80), or very good (0.80 to 
1.00). Statistical analyses were performed using STATA/SE ver. 14 




MRI confirmed the presence of fatty diffuse liver infiltration in all 
patients. Overall, according to our SOR (MRI), seven focal liver 
lesions (size range, 4 to 10 mm; mean, 6.1 mm) were detected 
in 4/37 patients (10.8%; age range, 43 to 70 years; mean, 53.3 
years) (Table 3). Four metastases (size range, 5 to 10 mm; mean, 
6.7 mm) were found in 3/37 patients (8.1%; age range, 43 to 70 
years; mean, 55.4 years), one patient with breast carcinoma and 
two patients with colorectal adenocarcinoma; whereas three benign 
lesions-one hemangioma and two cysts (size range, 4 to 6 mm; 
mean, 5.3 mm)-were detected in one of the already mentioned 
patients and in a fourth patient (Table 3). These four patients were 
followed up by means of US (interval range, 8 to 151 months; mean, 
62 months), without any statistically significant difference from the 
Fig. 1. A 53-year-old woman affected by breast cancer. 
A, B. Oblique ultrasonography of the right hepatic lobe shows geographic fatty infiltration of the liver, but no evidence of any focal liver 
lesion either before (A) or after contrast medium injection (B) (right side). C, D. An unenhanced T1-weighted “out of phase” magnetic 
resonance imaging image confirms geographic fatty change of the liver, but absence of lesions by showing a clear-cut inhomogeneous signal 
drop-out of hepatic parenchyma, in comparison with the “in phase” T1-weighted image (D).
C D
A B
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Fig. 2. Liver metastasis in a 70-year-old man (Table 3, patient 2). 
A. Parasagittal B-mode ultrasonography of the left lobe (right side, arrows) shows geographic fatty change of the liver but no evidence of 
any focal liver lesion whereas contrast-enhanced ultrasonography (left side) depicts a 0.5-cm-sized hypoechoic focal liver lesion in segment 
II during extended portal-venous phase (calipers). B-D. “In phase” (B) and “out of phase” (C) unenhanced magnetic resonance (MR) T1-
weighted images confirm geographic fatty infiltration of the liver and contrast-enhanced MR T1-weighted image in the portal-venous phase 
reveals the hypovascular metastasis (D) (arrow).
C D
A B
Table 3. Liver lesions as detected by standard of reference
Patient/sex/age (yr) Cancer type CEUS MRI Lesion size (mm) Liver segment Lesion type
1/F/52.8 CRC + + 7 IVa Metastasis
1/F/52.8 CRC - + 4 IVb Simple cyst
2/M/70.3 CRC + + 10 VII Metastasis
2/M/70.3 CRC + + 5 II Metastasis
3/F/43.2 Breast + + 5 IV Metastasis
4/F/46.8 Ovarian - + 6 II Hemangioma
4/F/46.8 Ovarian - + 6 III Simple cyst
CEUS, contrast-enhanced ultrasonography; MRI, magnetic resonance imaging; F, female; M, male; CRC, colorectal cancer; +, detected; -, undetected.
CEUS in cancer patients and diffuse liver steatosis
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Fig. 3. Hemangioma in a 47-year-old woman (Table 3, patient 4). 
A. Transverse ultrasonography of the left liver lobe shows geographic 
fatty change without any detectable focal liver lesion either at 
B-mode ultrasonography (left side, arrows) or contrast-enhanced 
ultrasonography (right side). B, C. “In phase” (B) and “out of 
phase” (C) unenhanced magnetic resonance (MR) T1-weighted 
images confirm geographic fatty infiltration of the liver and reveal a 
hypointense 6-mm-sized lesion in segment II (arrow). D, E. The lesion 
is hyperintense on heavily T2-weighted MR image (D) and shows 
homogeneous contrast-enhancement on T1-weighted MR image in 
the late phase (E) (arrows).
C D
A B
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remaining 32/37 patients (86.5%, P<0.05) (Fig. 1).
On a patient-by-patient basis, sensitivity, specificity, positive 
and negative predictive values, and accuracy of CEUS versus US, 
considering MRI as SOR, were 100% (95% confidence interval [CI], 
1.000 to 1.000), 97.1% (95% CI, 0.914 to 1.027), 75%, 100%, 
and 97.3%, respectively. Inter-observer agreement was very good, 
with a Cohen's kappa value of 0.8426 (95% CI, 0.5382 to 1.00).
Lesion-by-Lesion Analysis
CEUS detected all of the four metastases (size range, 5 to 10 
mm; mean, 6.7 mm) confirmed by MRI. All the metastases were 
hypoechoic in the portal-venous phase (Fig. 2). The MRI revealed 
three additional lesions: one cyst (4 mm) in patient number 1 of 
Table 1 and one capillary hemangioma and one cyst, each 6 mm in 
size, both undiscovered at CEUS in a woman aged 46.8 years with 
ovarian adenocarcinoma (Fig. 3). Finally, in 1/37 patients (2.7%), a 
63-year-old woman with endometrial cancer, CEUS misdiagnosed 
geographic fatty change mainly involving liver segments II, III, and 
IVa-sized 13, 40, and 46 mm, respectively-as three metastases (Fig. 4).
In a lesion-by-lesion analysis, the difference for both CEUS and 
MRI versus baseline US in the detection of focal liver lesions was 
statistically significant (P<0.001), whereas no statistically significant 
differences were found between CEUS versus MRI (P=0.480). No 
adverse events were registered in our patients during or immediately 
Fig. 4. A 63-year-old woman affected by endometrial cancer. 
A. Parasagittal baseline ultrasonography shows geographic fatty change in the left hepatic lobe (arrow). B. Contrast-enhanced 
ultrasonography shows a hypovascular area during the extended portal-venous phase (right side, arrow) misdiagnosed as metastasis. C, D. 
Unenhanced magnetic resonance image confirms geographic fatty change of the liver by depicting multiple hyperintense areas (arrows) of 
hepatic parenchyma on T1-weighted "in-phase" image (C) with a clear-cut signal drop-out in T1-weighted “out of phase” image (arrows) (D).
C D
A B
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after the injection of contrast agent. 
Discussion
In the present study, we focused on the detection of liver metastases 
during follow-up of cancer patients without any evidence of liver 
metastasis, but with geographic liver steatosis at baseline US. In 
this particular patient population, followed-up on average for more 
than 4 years, we found liver metastases at CEUS in a low but not 
negligible percentage of patients (8.1%), which is comparable to 
the lower end of the reported detection rates of liver metastases 
by CEUS (8% to 77%) [2,3,7,15]. An increase of sensitivity ranging 
from 4% up to 107% for the detection of liver metastases compared 
with baseline US has also been demonstrated by using CEUS [16,17]. 
However, there is no agreement about the usefulness of CEUS 
for screening and staging of metastases, and results in published 
studies are inconclusive, with some studies showing a similar 
diagnostic accuracy between CEUS and computed tomography/
MR imaging for the detection of liver metastases, while others find 
a significantly lower accuracy [2,3,7,15-20]. In our series, CEUS 
was able to detect all the metastases confirmed by MRI in patients 
with an inconclusive US study, thus leading to a dramatic change 
in patient management, ranging from radiofrequency thermal 
ablation to retreatment with chemotherapy. MRI detected no 
further metastases, but three benign lesions (2 cysts and 1 capillary 
hemangioma) even smaller than the metastases (mean size, 5.3 
mm vs. 6.7 mm). These findings, in spite of the observation that 
benign lesions are frequently encountered even in cancer patients, 
especially when smaller than 1.5 cm, suggest that it is mandatory to 
rule out liver metastases in cancer patients, even during prolonged 
follow-up and when lesions are smaller than 1 cm [21,22]. The 
6-mm hemangioma missed by CEUS in our study was located in the 
fatty area of the liver and was isoechoic both on B-mode US and on 
CEUS in the portal-venous phase, thus appearing indistinguishable 
from the adjacent liver parenchyma. One explanation for the two 
small, undetected cysts (6 mm and 4 mm) might be a potential 
blooming effect in the contrast agent that strongly enhanced the 
adjacent hepatic tissue, but further studies addressing this issue 
should be undertaken.
In addition, fatty change of the liver, often occurring in cancer 
patients undergoing chemotherapy and presenting with different 
patterns of deposition and sparing, may further hamper the proper 
assessment of these patients by means of US [2,12,14]. In particular, 
geographic fatty liver disease is a frequently encountered variant, 
sometimes occurring in the right lobe of the liver and related to 
lipogenic alimentary factors or to an insult to the liver parenchyma, 
such as cholangitis or chemotherapy [5]. In a study, CEUS showed 
a significantly improved sensitivity compared to unenhanced US 
(82.0% vs. 60.3%) for the detection of liver metastases from 
colorectal carcinoma after chemotherapeutic pretreatment [23,24]. 
In the present study, all the detected lesions were located in the fatty 
area of the liver. Although MRI performed slightly better than CEUS 
in the detection of liver lesions, no statistically significant difference 
was found, thus confirming the importance of CEUS in this particular 
clinical setting. In particular, the high negative predictive value of 
CEUS observed in our series (97%), which is quite similar to that 
reported by Rafaelsen et al. [3] (98%), suggests a role for CEUS as 
an effective first-line tool for ruling out the presence of metastases 
in cancer patients with inconclusive US study due to geographic 
fatty change of the liver, thus leaving the role of secondary problem 
solving to the more expensive procedure of MRI with liver-specific 
contrast agents [3,17,25,26].
Interestingly, in our series, CEUS misdiagnosed geographic 
fatty change mainly involving liver segments II, III, and IVa as liver 
metastases, because of the mildly hypoechoic appearance in the 
portal-venous phase. Although uncommon patterns of contrast-
enhancement of either fatty change or focal sparing in the liver have 
already been reported, to our knowledge this is the first report of 
an area of fatty change of the liver showing a hypoechoic pattern 
in the portal-venous phase [8,11,27]. This finding is partly related 
to the strict criteria adopted for malignancy in this study, where any 
hypoenhancing area in the portal-venous phase was considered 
malignant. Actually, the wedge shape, the subcapsular location, lack 
of mass effect, and undisturbed vessel traversing through the lesion 
could have suggested the correct diagnosis in a real clinical setting. 
Further studies are needed to address this issue, especially in 
oncologic patients, considering that false positive cases may include 
necrotic tissue, fibrotic scar, peliosis, hemangiomas, adenomas, and 
focal nodular hyperplasia [19,28]. However, our study confirms the 
already reported high inter-observer agreement in the assessment of 
liver by means of CEUS [27].
The main limitation of this study is that the final diagnosis 
was established in the majority of cases without pathological 
evaluation. However, all the lesions were well characterized at 
multiphase contrast-enhanced MRI on the basis of typical contrast-
enhancement patterns considered as established diagnostic criteria. 
Diffusion-weighted imaging (DWI) was not performed, which is an 
important sequence in the modern MRI liver protocol, although in 
one study Gd-EOB-DTPA-enhanced MRI showed higher accuracy in 
the detection of small metastases than DWI [29].
A selection bias is present in our study, since we only evaluated 
patients suitable for US. Nevertheless, this bias does not affect 
the results of the present study, but reflects the limitation of US in 
general. For the purpose of this work, in order to ensure the best 
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evaluation of both liver lobes, we decided to split the US contrast 
bolus into two consecutive injections with a 15-minute interval. In 
clinical practice, a single injection of 2.4 mL of contrast agent usually 
suffices to accomplish this task, thus sparing time and reducing 
costs even more [11].  
In conclusion, our results show that sulphur hexafluoride-
enhanced US improves the diagnostic performance of US in the 
detection of liver metastases in cancer patients with geographic 
liver fatty deposition but without any evidence of metastatic disease 
of the liver on conventional greyscale US. In this particular clinical 
setting, CEUS might be of immediate practical value for daily clinical 
practice and of substantial importance for patient care, with its use 
freeing resources and helping to optimize patient management by 
sparing time and avoiding unnecessary and costly MR scans.
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